Evaluating repetitive¹⁸F-fluoroazomycin-arabinoside (¹⁸FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer

Abstract

PET imaging with (18)FAZA is feasible in patients with cancer of the uterine cervix. However, its predictive and prognostic value remains to be clarified. This applies in particular for the additional value of (18)FAZA-PET compared to morphologic repetitive MRI within the setting of image guided high dose radiotherapy which may contribute to overcome hypoxia related radioresistance.